BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer.
William John Gradishar
No relevant relationships to disclose
Thomas Denis Bachelot
Research Funding - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Anne Marie Graham
Employment or Leadership Position - Novartis
Pedro Emanuel Rubini Liedke
No relevant relationships to disclose
Sergio Jobim Azevedo
No relevant relationships to disclose
Virote Sriuranpong
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Fatima Cardoso
Consultant or Advisory Role - Novartis
Research Funding - Novartis